Open AccessVildagliptin: the first innovative DDP-4 inhibitor
Author(s) -
Edvin Villkhauer,
Edvin Villkhauer
Publication year - 2010
Publication title -
saharnyj diabet
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.155
H-Index - 12
eISSN - 2072-0378
pISSN - 2072-0351
DOI - 10.14341/2072-0351-5499
Subject(s) - vildagliptin , sitagliptin , medicine , dipeptidyl peptidase 4 , pharmacology , dipeptidyl peptidase , saxagliptin , dipeptidyl peptidase 4 inhibitor , sitagliptin phosphate , type 2 diabetes mellitus , diabetes mellitus , type 2 diabetes , endocrinology , biochemistry , enzyme , chemistry
A review of the main stages of investigation undertaken by Novartis Pharmaceuticals in search of a new molecule for the treatment of type 2 diabetesmellitus, dipeptidyl peptidase-4 (DPP-4) inhibitor (Vildaglyptin). The data on specificity and selectivity of the action of this molecule are presentedalong with the results of its comparison with another agent of this group (sitagliptin).